Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel for Recurrent or Primary Advanced Endometrial Cancer (RUBY)
Metastatic endometrial cancer
Clinicaltrials.gov identifier:NCT03981796
Study Contact Information:
For additional information, please contact: US GSK Clinical Trials Call Center by phone: 877-379-3718 or by email: [email protected]
About the Study
This study for people with III or IV endometrial cancer will look at how well the combination of the dostarlimab (Jemperli), the niraparib () and chemotherapy works compared with chemotherapy alone. NOTE: This study is no longer enrolling people.
This Study is Open To:
NOTE: This study is no longer enrolling people.
This Study is NOT Open To:
NOTE: This study is no longer enrolling people.
Study Contact Information:
For additional information, please contact: US GSK Clinical Trials Call Center by phone: 877-379-3718 or by email: [email protected]
Metastatic endometrial cancer
Clinicaltrials.gov identifier:NCT03981796
Study Contact Information:
For additional information, please contact: US GSK Clinical Trials Call Center by phone: 877-379-3718 or by email: [email protected]